BACKGROUND AND HYPOTHESIS: Up to 43% of people with schizophrenia have a lifetime cannabis use disorder (CUD). Tetrahydrocannabinol (THC) has been shown to exacerbate psychosis in a dose-dependent manner, but little research has assessed its effects on schizophrenia and co-occurring CUD (SCZ-CUD). In this double-dummy, placebo-controlled trial (total n = 130), we hypothesized that a modest dose...
Nearly half of patients with schizophrenia (SCZ) have co-occurring cannabis use disorder (CUD), which has been associated with decreased treatment efficacy, increased risk of psychotic relapse, and poor global functioning. While reports on the effects of cannabis on cognitive performance in patients with SCZ have been mixed, study of brain networks related to executive function may clarify the...
JMIR Mental HealthAugust 21, 2017Lisa A Mistler, Dror Ben-Zeev, Elizabeth Carpenter-Song et al.
Aggression and violence on acute psychiatric inpatient units is extensive and leads to negative sequelae for staff and patients. With increasingly acute inpatient milieus due to shorter lengths of stay, inpatient staff is limited in training and time to be able to provide treatments. Mobile technology provides a new platform for offering treatment on such units, but it has not been tested for...
Jeff W. Jin, Nolan J. Neu, Isaac B. Satz et al.
preprint
Background Cannabis use is associated with psychosis development and symptom relapse in persons with schizophrenia spectrum disorders (SCZ). As more U.S. states legalize cannabis and products increase in potency, it is crucial to better understand recent cannabis use patterns in SCZ. Methods We conducted a scoping review of research on cannabis use patterns in SCZ after January 2016 and present...